PAM
BTAI icon

Panagora Asset Management’s BioXcel Therapeutics BTAI Stock Holding History

Panagora Asset Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,079
Closed -$745K – 2792
2021
Q1 		$745K Hold
1,079
– – ﹤0.01% 1147
2020
Q4 		$797K Buy
1,079
+204
+23% +$159K ﹤0.01% 1059
2020
Q3 		$607K Sell
875
-1,269
-59% -$953K ﹤0.01% 1088
2020
Q2 		$1.82M Buy
+2,144
New +$1.4M 0.01% 708

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AS
Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

Panagora Asset Management's BTAI Position: Q2 2021 in Review

Panagora Asset Management sold out of BioXcel Therapeutics (BTAI) in Q2 2021, closing a stake of 1,079 shares — an estimated $745K sold.

Panagora Asset Management first reported a position in BTAI in Q2 2020 and held it in 4 quarters. The position peaked at $1.82M in Q2 2020. 108 funds tracked by Wall St. Rank hold BTAI as of Q2 2021.

  • Panagora Asset Management reported no remaining BioXcel Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Panagora Asset Management sold 1,079 BioXcel Therapeutics shares in Q2 2021, an estimated $745K.
  • Panagora Asset Management first reported a position in BioXcel Therapeutics in Q2 2020 and held it in 4 quarters.
  • Panagora Asset Management's BioXcel Therapeutics position peaked at $1.82M in Q2 2020.
  • 108 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2021.

Based on Panagora Asset Management's 13F filing for Q2 2021, filed 11 Aug 2021.